CJC-1295 + Ipamorelin is a synergistic combination of two growth hormone secretagogues. CJC-1295 (modified GRF 1-29) extends GHRH signaling via albumin binding, while Ipamorelin is a selective ghrelin receptor agonist. Research examines their combined effect on pulsatile GH release patterns. Research compound — for laboratory use only.
Compound Specifications
CJC-1295 + Ipamorelin is a research blend combining a modified growth hormone-releasing hormone analog (CJC-1295 / Mod GRF 1-29, CAS 863288-34-0) with a selective growth hormone secretagogue pentapeptide (ipamorelin, CAS 170851-70-4). CJC-1295 acts at the GHRH receptor while ipamorelin acts at the ghrelin/GHS receptor, representing two distinct GH-axis targets. Research compound — for laboratory use only.
Product Details
- Compound: CJC-1295 (No DAC) + Ipamorelin
- Contents: Modified GRF 1-29 and Ipamorelin
- Purity: High
- Form: Lyophilized powder
- Sizes: 5mg blend, 10mg blend
- Testing: View COA (Verified by Janoshik) →
📚 View Published Research on CJC-1295 + Ipamorelin →
Peer-reviewed citations from PubMed — for educational purposes only



